Eczema Trial, Recruiting NCT07183423 Sponsor: Makati Medical Center Condition: Eczema
Back to Eczema

Eczema Trial, Recruiting

NCT07183423
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with a mild skin barrier condition, such as mild to moderate atopic dermatitis (eczema), mild to moderate chronic plaque psoriasis, contact dermatitis, or dry/flaky skin that occurs seasonally or is visibly noticeable
  • People whose eczema is considered mild to moderate, meaning their condition scores 50 or below on a standard medical scale, and who are not currently using prescription creams or ointments to manage it
  • People whose psoriasis affects a small to moderate portion of the body (roughly 3% to 10% of total body surface area)
  • People who have matching test areas available on the inner side of both forearms
  • People who are willing and able to give their agreement to participate and follow the study procedures

Who may not be able to join:

  • People with severe eczema or psoriasis that requires strong prescription treatments, either taken by mouth/injection or applied to the skin
  • People who have used steroid creams, certain immune-suppressing treatments, biologic medications, or light therapy within the past 2 weeks
  • People who have open wounds or signs of skin infection at the areas to be tested
  • People who are pregnant or breastfeeding
  • People who have many moles, tattoos, or thick body hair in the test areas on the forearms
  • People who are in poor general health or have a weakened immune system
  • People with a known or suspected allergy to the study product, any of its ingredients, or to petrolatum (petroleum jelly)
  • People who are unwilling or unable to attend all required visits at the trial site

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Vermen M Verallo Rowell, MD, VMV Skin Research Center & Clinics

Phone: 639171478318

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Makati Medical Center
Registry
ClinicalTrials.gov
Start date
31 August 2025
Est. completion
1 September 2025

Where this trial is recruiting

🇵🇭 Philippines

Primary endpoints

Transepidermal water loss; Skin hydration; Skin sebum; Skin erythema and pigmentation

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov